Shares of Versartis, Inc. (NASDAQ:VSAR) have been assigned an average recommendation of “Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $26.29.
A number of research firms recently weighed in on VSAR. Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. BidaskClub lowered shares of Versartis from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $28.00 price objective on shares of Versartis and gave the stock a “buy” rating in a research note on Sunday, May 28th. Piper Jaffray Companies set a $26.00 target price on shares of Versartis and gave the stock a “buy” rating in a report on Tuesday, June 27th. Finally, ValuEngine upgraded shares of Versartis from a “sell” rating to a “hold” rating in a report on Friday, June 2nd.
Shares of Versartis (NASDAQ:VSAR) traded up 3.32% on Monday, hitting $17.10. 225,453 shares of the company traded hands. Versartis has a 1-year low of $9.05 and a 1-year high of $24.00. The firm’s market capitalization is $608.38 million. The firm’s 50-day moving average is $17.84 and its 200 day moving average is $17.95.
Versartis (NASDAQ:VSAR) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.20. On average, analysts anticipate that Versartis will post ($3.29) earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in VSAR. Russell Investments Group Ltd. purchased a new position in shares of Versartis during the fourth quarter worth approximately $116,000. First Quadrant L P CA bought a new position in Versartis during the second quarter valued at about $155,000. Bank of America Corp DE increased its position in Versartis by 46.3% in the first quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 3,001 shares during the period. Metropolitan Life Insurance Co. NY increased its position in Versartis by 22.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 23,257 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 4,270 shares during the period. Finally, UBS Group AG bought a new position in Versartis during the first quarter valued at about $367,000. Institutional investors and hedge funds own 77.88% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Versartis, Inc. (VSAR) Given Average Recommendation of “Buy” by Analysts” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.com-unik.info/2017/08/11/versartis-inc-vsar-receives-average-recommendation-of-buy-from-brokerages-updated-updated-updated.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
What are top analysts saying about Versartis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Versartis Inc. and related companies.